| Work Detail |
Piramal Pharma Solutions, the contract development and manufacturing arm of Piramal Pharma Ltd (PPL), has announced an $80 million (?670 crore) investment to expand its Lexington, Kentucky facility. The project will add 24,000 square feet of manufacturing space, a new laboratory, and advanced machinery to enhance the sites capacity and capabilities.
The expansion will introduce key upgrades, including a new filling line, two commercial-size lyophilisers, a capping machine, and an external vial washer. The facility’s annual production capacity will increase from 104 to over 240 product batches by the time the expansion is completed in Q1 of 2027, and 40 full-time jobs will be created.
The Lexington site specializes in sterile compounding, liquid filling, and lyophilization for injectable drug products. It also plays a critical role in Piramal Pharma’s ADCelerate program, focused on antibody-drug conjugate development and manufacturing. Several clients have already committed to commercializing their products at the expanded facility, marking a significant milestone for Piramal Pharma.
Financed through bank loans and internal accruals, the investment aims to position Piramal Pharma as a stronger player in the rapidly growing injectables market, projected to exceed $20 billion by 2028. The company sees this expansion as a strategic move to meet increasing market demand and solidify its role as a global partner in biologic manufacturing.
"This expansion fills the gap in commercial manufacturing and strengthens Piramal Pharma’s presence in the injectables market," said Nandini Piramal, Chairperson of PPL. Peter DeYoung, CEO of Global Pharma, added, "With rising demand and insufficient supply in the injectables market, we are committed to adapting and positioning ourselves as a comprehensive partner throughout the product life cycle." |
